{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:36:06Z","timestamp":1787614566679,"version":"build-2736575974"},"reference-count":67,"publisher":"Portland Press Ltd.","issue":"9","license":[{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Worldwide, ovarian cancer (OC) is the seventh common cancer and the second most common cause of cancer death in women. Due to high rates of relapse, there is an urgent need for the identification of new targets for OC treatment. The far-upstream element binding protein 1 (FBP1) and enhancer of zeste homolog 2 (EZH2) are emerging proto-oncogenes that regulate cell proliferation and metastasis. In the present study, Oncomine data analysis demonstrated that FBP1 was closely associated with the development of OC, and The Cancer Genome Atlas (TCGA) data analysis indicated that there was a positive correlation between FBP1 and EZH2 in ovarian tissues. Moreover, we found that FBP1 knockdown suppressed tumor formation in nude mice and cisplatin resistance of OC cells, but the role of FBP1 in the cisplatin resistance of OC cells remained unclear. In addition, we verified physical binding between FBP1 and EZH2 in OC cells, and we demonstrated that FBP1 knockdown enhanced cisplatin cytotoxicity in OC cells and down-regulated EZH2 expression and trimethylation of H3K27. These results suggested that FBP1 increases cisplatin resistance of OC cells by up-regulating EZH2\/H3K27me3. Thus, FBP1 is a prospective novel target for the development of OC treatment.<\/jats:p>","DOI":"10.1042\/bsr20221002","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T11:10:34Z","timestamp":1661339434000},"update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["FBP1 knockdown decreases ovarian cancer formation and cisplatin resistance through EZH2-mediated H3K27me3"],"prefix":"10.1042","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3257-0879","authenticated-orcid":false,"given":"Xifeng","family":"Xiong","sequence":"first","affiliation":[{"name":"1Guangzhou Institute of Traumatic Surgery, Guangzhou Red Cross Hospital of Jinan University, Guangzhou 510220, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Lai","sequence":"additional","affiliation":[{"name":"2Department of Infectious Diseases, Guangzhou Red Cross Hospital of Jinan University, Guangzhou 510220, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinli","family":"Zhang","sequence":"additional","affiliation":[{"name":"1Guangzhou Institute of Traumatic Surgery, Guangzhou Red Cross Hospital of Jinan University, Guangzhou 510220, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqi","family":"Meng","sequence":"additional","affiliation":[{"name":"1Guangzhou Institute of Traumatic Surgery, Guangzhou Red Cross Hospital of Jinan University, Guangzhou 510220, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengzhen","family":"Wang","sequence":"additional","affiliation":[{"name":"1Guangzhou Institute of Traumatic Surgery, Guangzhou Red Cross Hospital of Jinan University, Guangzhou 510220, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengnan","family":"Qin","sequence":"additional","affiliation":[{"name":"1Guangzhou Institute of Traumatic Surgery, Guangzhou Red Cross Hospital of Jinan University, Guangzhou 510220, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[{"name":"3Department of Breast Surgery, Guangzhou Red Cross Hospital of Jinan University, Guangzhou 510220, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxuan","family":"Wang","sequence":"additional","affiliation":[{"name":"4Department of Pathology, Guangzhou Red Cross Hospital of Jinan University, Guangzhou 510220, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Yao","sequence":"additional","affiliation":[{"name":"5School of Life Sciences and biopharmaceutics, Guangdong Pharmaceutical University, Panyu District, Guangzhou 510006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wang","sequence":"additional","affiliation":[{"name":"6Department of Rehabilitation Medicine, The Second Affiliated Hospital of Guangzhou Medical University, 250 Changgang East Road, Guangzhou 510260, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojian","family":"Li","sequence":"additional","affiliation":[{"name":"7Department of Burn and Plastic Surgery, Guangzhou Red Cross Hospital of Jinan University, Guangzhou 510220, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihe","family":"Liu","sequence":"additional","affiliation":[{"name":"1Guangzhou Institute of Traumatic Surgery, Guangzhou Red Cross Hospital of Jinan University, Guangzhou 510220, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixiong","family":"Miao","sequence":"additional","affiliation":[{"name":"8Department of Orthopedic Surgery, Guangzhou Red Cross Hospital of Jinan University, Guangzhou 510220, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2022,9,7]]},"reference":[{"key":"2022090708205051300_B1","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1111\/cas.14317","article-title":"Application of the microRNA-302\/367 cluster in cancer therapy","volume":"111","author":"Liu","year":"2020","journal-title":"Cancer Sci."},{"key":"2022090708205051300_B2","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.7150\/jca.31166","article-title":"The role of Wnt signaling pathway in tumor metabolic reprogramming","volume":"10","author":"Mo","year":"2019","journal-title":"J. Cancer"},{"key":"2022090708205051300_B3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/cdd.2017.171","article-title":"Deconstructing networks of p53-mediated tumor suppression in vivo","volume":"25","author":"Kaiser","year":"2018","journal-title":"Cell Death Differ."},{"key":"2022090708205051300_B4","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s13238-014-0065-9","article-title":"The genetic and epigenetic alterations in human hepatocellular carcinoma: a recent update","volume":"5","author":"Liu","year":"2014","journal-title":"Protein Cell"},{"key":"2022090708205051300_B5","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1146\/annurev-immunol-073119-095439","article-title":"Caspases in cell death, inflammation, and pyroptosis","volume":"38","author":"Kesavardhana","year":"2020","journal-title":"Annu. Rev. Immunol."},{"key":"2022090708205051300_B6","doi-asserted-by":"publisher","first-page":"4443","DOI":"10.1158\/0008-5472.CAN-16-0774","article-title":"HOXC10 expression supports the development of chemotherapy resistance by fine tuning DNA repair in breast cancer cells","volume":"76","author":"Sadik","year":"2016","journal-title":"Cancer Res."},{"key":"2022090708205051300_B7","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.devcel.2019.03.015","article-title":"Oncogenic Notch triggers neoplastic tumorigenesis in a transition-zone-like tissue microenvironment","volume":"49","author":"Yang","year":"2019","journal-title":"Dev. Cell"},{"key":"2022090708205051300_B8","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1002\/ijc.30676","article-title":"International patterns and trends in ovarian cancer incidence, overall and by histologic subtype","volume":"140","author":"Coburn","year":"2017","journal-title":"Int. J. Cancer"},{"key":"2022090708205051300_B9","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"2022090708205051300_B10","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","article-title":"Ovarian cancer","volume":"384","author":"Jayson","year":"2014","journal-title":"Lancet"},{"key":"2022090708205051300_B11","first-page":"426","article-title":"Advances in the management of epithelial ovarian cancer","volume":"50","author":"Berkenblit","year":"2005","journal-title":"J. Reprod. Med."},{"key":"2022090708205051300_B12","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1097\/00001622-200209000-00008","article-title":"Management of recurrent ovarian cancer: evidence-based decisions","volume":"14","author":"Salom","year":"2002","journal-title":"Curr. Opin. Oncol."},{"key":"2022090708205051300_B13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"2022090708205051300_B14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3322\/canjclin.51.1.15","article-title":"Cancer statistics, 2001","volume":"51","author":"Greenlee","year":"2001","journal-title":"CA Cancer J. Clin."},{"key":"2022090708205051300_B15","doi-asserted-by":"publisher","first-page":"764323","DOI":"10.1155\/2014\/764323","article-title":"Ovarian cancer","volume":"2014","author":"Song","year":"2014","journal-title":"BioMed Res. Int."},{"key":"2022090708205051300_B16","doi-asserted-by":"publisher","first-page":"18538","DOI":"10.1016\/S0021-9258(17)44785-5","article-title":"A far upstream element stimulates c-myc expression in undifferentiated leukemia cells","volume":"265","author":"Avigan","year":"1990","journal-title":"J. Biol. Chem."},{"key":"2022090708205051300_B17","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1038\/onc.2012.350","article-title":"Far upstream element binding protein 1: a commander of transcription, translation and beyond","volume":"32","author":"Zhang","year":"2013","journal-title":"Oncogene"},{"key":"2022090708205051300_B18","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1002\/hep.23051","article-title":"Overexpression of far upstream element binding proteins: a mechanism regulating proliferation and migration in liver cancer cells","volume":"50","author":"Malz","year":"2009","journal-title":"Hepatology"},{"key":"2022090708205051300_B19","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1002\/hep.23098","article-title":"Overexpression of the far upstream element binding protein 1 in hepatocellular carcinoma is required for tumor growth","volume":"50","author":"Rabenhorst","year":"2009","journal-title":"Hepatology"},{"key":"2022090708205051300_B20","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1126\/science.1210557","article-title":"Mutations in CIC and FUBP1 contribute to human oligodendroglioma","volume":"333","author":"Bettegowda","year":"2011","journal-title":"Science"},{"key":"2022090708205051300_B21","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1158\/0008-5472.CAN-08-3338","article-title":"Coordinated expression of stathmin family members by far upstream sequence element-binding protein-1 increases motility in non-small cell lung cancer","volume":"69","author":"Singer","year":"2009","journal-title":"Cancer Res."},{"key":"2022090708205051300_B22","doi-asserted-by":"publisher","first-page":"6189","DOI":"10.1038\/onc.2016.151","article-title":"MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1","volume":"35","author":"Venturutti","year":"2016","journal-title":"Oncogene"},{"key":"2022090708205051300_B23","doi-asserted-by":"publisher","first-page":"e0169852","DOI":"10.1371\/journal.pone.0169852","article-title":"Upregulation of far upstream element-binding protein 1 (FUBP1) promotes tumor proliferation and tumorigenesis of clear cell renal cell carcinoma","volume":"12","author":"Duan","year":"2017","journal-title":"PLoS ONE"},{"key":"2022090708205051300_B24","doi-asserted-by":"publisher","first-page":"5761","DOI":"10.1128\/JVI.00064-08","article-title":"The FUSE binding protein is a cellular factor required for efficient replication of hepatitis C virus","volume":"82","author":"Zhang","year":"2008","journal-title":"J. Virol."},{"key":"2022090708205051300_B25","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1186\/1471-2407-14-925","article-title":"Fuse binding protein antagonizes the transcription activity of tumor suppressor protein p53","volume":"14","author":"Dixit","year":"2014","journal-title":"BMC Cancer"},{"key":"2022090708205051300_B26","doi-asserted-by":"publisher","first-page":"7905","DOI":"10.1128\/JVI.00729-15","article-title":"FUSE binding protein 1 facilitates persistent hepatitis C virus replication in hepatoma cells by regulating tumor suppressor p53","volume":"89","author":"Dixit","year":"2015","journal-title":"J. Virol."},{"key":"2022090708205051300_B27","doi-asserted-by":"publisher","first-page":"9633","DOI":"10.1093\/nar\/gkr682","article-title":"Far upstream element binding protein 1 binds the internal ribosomal entry site of enterovirus 71 and enhances viral translation and viral growth","volume":"39","author":"Huang","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"2022090708205051300_B28","doi-asserted-by":"publisher","first-page":"e1005959","DOI":"10.1371\/journal.ppat.1005959","article-title":"Additive promotion of viral internal ribosome entry site-mediated translation by far upstream element-binding protein 1 and an enterovirus 71-induced cleavage product","volume":"12","author":"Hung","year":"2016","journal-title":"PLoS Pathog."},{"key":"2022090708205051300_B29","doi-asserted-by":"publisher","first-page":"5819","DOI":"10.3892\/ol.2017.6978","article-title":"Knockdown of FUSE binding protein 1 enhances the sensitivity of epithelial ovarian cancer cells to carboplatin","volume":"14","author":"Zhang","year":"2017","journal-title":"Oncol. Lett."},{"key":"2022090708205051300_B30","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.3892\/ol.2018.8872","article-title":"FBP1 promotes ovarian cancer development through the acceleration of cell cycle transition and metastasis","volume":"16","author":"Xiong","year":"2018","journal-title":"Oncol. Lett."},{"key":"2022090708205051300_B31","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/CAD.0000000000000166","article-title":"S-Adenosyl-L-methionine-competitive inhibitors of the histone methyltransferase EZH2 induce autophagy and enhance drug sensitivity in cancer cells","volume":"26","author":"Liu","year":"2015","journal-title":"Anticancer Drugs"},{"key":"2022090708205051300_B32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.molcel.2019.03.011","article-title":"Molecular mechanisms directing PRC2 recruitment and H3K27 methylation","volume":"74","author":"Laugesen","year":"2019","journal-title":"Mol. Cell"},{"key":"2022090708205051300_B33","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41594-018-0036-6","article-title":"Accurate H3K27 methylation can be established de novo by SUZ12-directed PRC2","volume":"25","author":"H\u00f8jfeldt","year":"2018","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2022090708205051300_B34","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0092-8674(02)00975-3","article-title":"Drosophila enhancer of Zeste\/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites","volume":"111","author":"Czermin","year":"2002","journal-title":"Cell"},{"key":"2022090708205051300_B35","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41467-018-03031-3","article-title":"CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity","volume":"9","author":"Karakashev","year":"2018","journal-title":"Nat. Commun."},{"key":"2022090708205051300_B36","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.cellsig.2016.02.004","article-title":"EZH2, an on-off valve in signal network of tumor cells","volume":"28","author":"Sun","year":"2016","journal-title":"Cell. Signal."},{"key":"2022090708205051300_B37","doi-asserted-by":"publisher","first-page":"4028","DOI":"10.1158\/0008-5472.CAN-10-3342","article-title":"EZH2-mediated concordant repression of Wnt antagonists promotes beta-catenin-dependent hepatocarcinogenesis","volume":"71","author":"Cheng","year":"2011","journal-title":"Cancer Res."},{"key":"2022090708205051300_B38","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/onc.2017.311","article-title":"EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer","volume":"37","author":"Yamaguchi","year":"2017","journal-title":"Oncogene"},{"key":"2022090708205051300_B39","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1097\/JTO.0b013e318298762f","article-title":"EZH2 promotes E2F-driven SCLC tumorigenesis through modulation of apoptosis and cell-cycle regulation","volume":"8","author":"Hubaux","year":"2013","journal-title":"J. Thoracic Oncol."},{"key":"2022090708205051300_B40","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.mrfmmm.2008.07.010","article-title":"Roles of the EZH2 histone methyltransferase in cancer epigenetics","volume":"647","author":"Simon","year":"2008","journal-title":"Mutat. Res."},{"key":"2022090708205051300_B41","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.7150\/jca.26275","article-title":"EZH2 Expression is increased in BAP1-mutant renal clear cell carcinoma and is related to poor prognosis","volume":"9","author":"Sun","year":"2018","journal-title":"J. Cancer"},{"key":"2022090708205051300_B42","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1182\/blood-2017-08-804344","article-title":"Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas","volume":"131","author":"Bisserier","year":"2018","journal-title":"Blood"},{"key":"2022090708205051300_B43","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s12029-017-9985-y","article-title":"Predicting the correlation of EZH2 and cancer stem cell markers in esophageal squamous cell carcinoma","volume":"49","author":"Karami Madani","year":"2018","journal-title":"J. Gastrointestinal Cancer"},{"key":"2022090708205051300_B44","doi-asserted-by":"publisher","first-page":"788","DOI":"10.4161\/cbt.10.8.12913","article-title":"Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo","volume":"10","author":"Hu","year":"2010","journal-title":"Cancer Biol. Therapy"},{"key":"2022090708205051300_B45","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1111\/cas.13599","article-title":"Enhancer of zeste homolog 2 promotes cisplatin resistance by reducing cellular platinum accumulation","volume":"109","author":"Sun","year":"2018","journal-title":"Cancer Sci."},{"key":"2022090708205051300_B46","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1080\/15384047.2019.1680061","article-title":"GSK343 induces programmed cell death through the inhibition of EZH2 and FBP1 in osteosarcoma cells","volume":"21","author":"Xiong","year":"2020","journal-title":"Cancer Biol. Therapy"},{"key":"2022090708205051300_B47","doi-asserted-by":"publisher","first-page":"623","DOI":"10.3892\/ijo.2016.3541","article-title":"Fuse-binding protein 1 is a target of the EZH2 inhibitor GSK343, in osteosarcoma cells","volume":"49","author":"Xiong","year":"2016","journal-title":"Int. J. Oncol."},{"key":"2022090708205051300_B48","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1111\/j.1349-7006.2009.01204.x","article-title":"Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis","volume":"100","author":"Yoshihara","year":"2009","journal-title":"Cancer Sci."},{"key":"2022090708205051300_B49","doi-asserted-by":"publisher","first-page":"4960","DOI":"10.1158\/1078-0432.CCR-14-3173","article-title":"Creation of a human secretome: a novel composite library of human secreted proteins: validation using ovarian cancer gene expression data and a virtual secretome array","volume":"21","author":"Vathipadiekal","year":"2015","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"key":"2022090708205051300_B50","doi-asserted-by":"publisher","first-page":"7104","DOI":"10.1038\/s41598-017-07005-1","article-title":"Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cells","volume":"7","author":"Sonego","year":"2017","journal-title":"Sci. Rep."},{"key":"2022090708205051300_B51","doi-asserted-by":"publisher","first-page":"6356","DOI":"10.1158\/1078-0432.CCR-11-0735","article-title":"BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival","volume":"17","author":"Marchion","year":"2011","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"key":"2022090708205051300_B52","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/978-1-4939-3578-9_6","article-title":"A practical guide to The Cancer Genome Atlas (TCGA)","volume":"1418","author":"Wang","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"2022090708205051300_B53","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00018-018-2933-6","article-title":"The master regulator FUBP1: its emerging role in normal cell function and malignant development","volume":"76","author":"Debaize","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"2022090708205051300_B54","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.1007\/s13277-015-4263-8","article-title":"Far upstream element-binding protein 1 (FUBP1) is a potential c-Myc regulator in esophageal squamous cell carcinoma (ESCC) and its expression promotes ESCC progression","volume":"37","author":"Yang","year":"2016","journal-title":"Tumour Biol.: J. Int. Soc. Oncodevelopmental Biol. Med."},{"key":"2022090708205051300_B55","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/mc.22114","article-title":"Expression of far upstream element (FUSE) binding protein 1 in human glioma is correlated with c-Myc and cell proliferation","volume":"54","author":"Ding","year":"2015","journal-title":"Mol. Carcinog."},{"key":"2022090708205051300_B56","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","article-title":"A view on drug resistance in cancer","volume":"575","author":"Vasan","year":"2019","journal-title":"Nature"},{"key":"2022090708205051300_B57","doi-asserted-by":"publisher","first-page":"16061","DOI":"10.1038\/nrdp.2016.61","article-title":"Ovarian cancer","volume":"2","author":"Matulonis","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"2022090708205051300_B58","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: role of ATP-dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"2022090708205051300_B59","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1038\/sj.onc.1209377","article-title":"Cytochrome P450 pharmacogenetics and cancer","volume":"25","author":"Rodriguez-Antona","year":"2006","journal-title":"Oncogene"},{"key":"2022090708205051300_B60","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nrc1893","article-title":"Drug penetration in solid tumours","volume":"6","author":"Minchinton","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"2022090708205051300_B61","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nrc2714","article-title":"Environment-mediated drug resistance: a major contributor to minimal residual disease","volume":"9","author":"Meads","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"2022090708205051300_B62","first-page":"16941","article-title":"Knockdown of CIP2A sensitizes ovarian cancer cells to cisplatin: an in vitro study","volume":"8","author":"Zhang","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"2022090708205051300_B63","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1158\/0008-5472.CAN-19-0542","article-title":"Targeting the high-mobility group box 3 protein sensitizes chemoresistant ovarian cancer cells to cisplatin","volume":"79","author":"Mukherjee","year":"2019","journal-title":"Cancer Res."},{"key":"2022090708205051300_B64","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nm.4036","article-title":"Targeting EZH2 in cancer","volume":"22","author":"Kim","year":"2016","journal-title":"Nat. Med."},{"key":"2022090708205051300_B65","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/CCO.0000000000000390","article-title":"Targeting EZH2 in cancer therapy","volume":"29","author":"Yamagishi","year":"2017","journal-title":"Curr. Opin. Oncol."},{"key":"2022090708205051300_B66","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1158\/1535-7163.MCT-17-0437","article-title":"Histone methyltransferase EZH2: a therapeutic target for ovarian cancer","volume":"17","author":"Jones","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"2022090708205051300_B67","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1089\/cbr.2016.2034","article-title":"Interfering EZH2 expression reverses the cisplatin resistance in human ovarian cancer by inhibiting autophagy","volume":"31","author":"Sun","year":"2016","journal-title":"Cancer Biother. Radiopharmaceut."}],"container-title":["Bioscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20221002\/936886\/bsr-2022-1002.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20221002\/936886\/bsr-2022-1002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T08:21:17Z","timestamp":1662538877000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/bioscirep\/article\/42\/9\/BSR20221002\/231685\/FBP1-knockdown-decreases-ovarian-cancer-formation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":67,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9,30]]}},"URL":"https:\/\/doi.org\/10.1042\/bsr20221002","relation":{},"ISSN":["0144-8463","1573-4935"],"issn-type":[{"value":"0144-8463","type":"print"},{"value":"1573-4935","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,9]]},"published":{"date-parts":[[2022,9]]},"article-number":"BSR20221002"}}